- Home
- WRBY vs RCKT Comparison
WRBY vs RCKT Comparison
Compare WRBY & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | RCKT |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 340.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | WRBY | RCKT |
|---|---|---|
| Price | $26.71 | $3.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | $25.43 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 5.7M | 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | N/A |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $12.84 | N/A |
| P/E Ratio | $10,619.72 | ★ N/A |
| Revenue Growth | ★ 14.55 | N/A |
| 52 Week Low | $13.63 | $2.19 |
| 52 Week High | $31.00 | $13.35 |
Technical Indicators
Market Signals| Indicator | WRBY | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 56.13 |
| Support Level | $25.78 | $3.19 |
| Resistance Level | $27.96 | $3.57 |
| Average True Range (ATR) | 2.01 | 0.20 |
| MACD | 0.36 | 0.01 |
| Stochastic Oscillator | 66.25 | 78.18 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.